Eli Lilly's Zepbound is being directly compared to Novo Nordisk's Wegovy in the SURMOUNT-5 trial, with results expected by year-end, potentially impacting market perception.
Novo Nordisk's oral amycretin demonstrated a 4% placebo-adjusted weight loss after four weeks, showing potential in glucose control and appetite regulation.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.